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1. Introduction 
Meningiomas are solid tumors of the Central Nervous System arising from arachnoid layer 
cells, which cover the brain and spinal cord. Meningiomas account for about 34% of primary 
intracranial tumors, with an annual incidence rate of 6.17 per 100,000 person-year, as 
reported in a recent population-based study (Yee G. 2009). Many small meningiomas go 
unnoticed during life and are found incidentally in up to 1.4% of people in autopsy series 
(Rohringer, Sutherland et al. 1989).  
In general, meningiomas display a broad range of histological patterns. The current World 
Health Organization (WHO) classification lists 16 different variants or subtypes, falling into 3 
grade designations. The WHO classification of tumors of the nervous system distinguishes 
between grade I (benign), grade II (atypical) and grade III (anaplastic or malignant) 
meningiomas (Table 1, Fig. 1) (Perry, Louis et al. 2007). About 90% of all meningiomas are 
slowly growing benign tumors of WHO grade I. Atypical meningiomas constitute about 6-8% 
of cases, although using more current definitions, it has been reported in up to 20%. These 
WHO grade II meningiomas are histologically defined by increased mitotic activity (four or 
more mitoses per 10 high-power microscopic fields) and/or at least three of the following 
criteria: increased cellularity, high nucleus/cytoplasm ratio, prominent nucleoli, uninterrupted 
patternless or sheet-like growth and necrosis. Approximately 2-3% of all meningiomas show 
histological features of frank malignancy, including a high level of mitotic activity (20 or more 
mitosis per 10 high-power microscopic fields) and/or a histological appearance similar to 
sarcoma, carcinoma or melanoma (Perry, Louis et al. 2007).  
Tumor recurrence is the major clinical complication in meningiomas, occurring in 10-15% 
and 25-37% of patients undergoing curative surgery after 5- and 10-year follow-up periods, 
respectively (Mirimanoff, Dosoretz et al. 1985; Maillo, Orfao et al. 2007). The most important 
factors that determine the recurrence of meningiomas are the extension of the tumor 
resection and the histologic grade (Riemenschneider, Perry et al. 2006; Louis, Ohgaki et al. 
2007). Therefore, prediction of relapse occurrence in meningiomas during the first few years 
following diagnostic surgery still remains a major challenge. 
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Up to date, none of the common genetic alterations of meningiomas have acquired clinical 
relevance. However, the analysis of these alterations in relation to histological grade has led 
to a model in which genetic aberrations are presumably involved in the formation of 
meningiomas, with subsequent alterations associated with tumor progression (Lomas, Bello 
et al. 2005; Martinez-Glez, Franco-Hernandez et al. 2008). 
Meningiomas were among the first solid tumors recognized as being characterized by a 
specific cytogenetic alteration, which is monosomy 22. Since then, loss of genetic material 
from chromosome 22 has been the most consistent aberration, observed in up to 70% of 
tumors (Perry, Louis et al. 2007; Martinez-Glez, Franco-Hernandez et al. 2009).  
Familial occurrence of meningiomas is found in patients with neurofibromatosis type 2 (NF2), 
usually with multiple meningiomas, as also occurs in other non-NF2 families with 
predisposition to meningioma. Approximately 50% of NF2 patients suffer from meningiomas, 
making them the second most frequent neoplasm associated with this tumor syndrome. 
Sporadic meningiomas were then screened for mutations in the NF2 gene, which was found to 
be frequently inactivated in up to 60-70% of meningiomas. Therefore, the NF2 gene, located at 
22q12.2, is considered the main candidate for the genesis of meningiomas, having a role as a 
tumor suppressor gene (TSG) (Louis DN and JJ 2000; Martínez-Glez V. 2007). 
 
Meningiomas with low risk of recurrence and aggressive growth
WHO grade I 
Meningothelial meningioma 
Fibrous (fibroblastic) meningioma
Transitional (mixed) meningioma
Psammomatous meningioma
Angiomatous meningioma
Microcystic meningioma
Secretory meningioma
Lymphoplasmacyte-rich meningioma
Metaplasic meningioma
Meningiomas with greater risk of recurrence and aggressive growth
WHO grade II 
Chordoid meningioma 
Clear cell meningioma
Atypical meningioma
WHO grade III 
Papillary meningioma 
Rhabdoid meningioma 
Anaplastic (malignant) meningioma 
Table 1. Meningioma grouped by likelihood of recurrence and grade (Perry, Louis et al. 2007). 
Other cytogenetic changes secondary to the 22q anomaly, and which are involved in tumor 
progression to atypical and anaplastic meningiomas, are losses of 1p, 6q, 14q, chr.10, 18q, 
and gains of 1q, 9q, 12q, 15q, 17q, and 20q (Bello, de Campos et al. 1994; Perry, Gutmann et 
al. 2004; Perry, Louis et al. 2007; Martinez-Glez, Franco-Hernandez et al. 2009). 
Epigenetic alterations seem also to play an important role in the tumorigenesis of 
meningiomas, as occurs in many other tumor types. These alterations indicate that the 
silencing by aberrant hypermethylation of gene promoter regions contributes to the genesis 
and tumor progression of meningiomas (Martinez-Glez, Franco-Hernandez et al. 2008). In 
www.intechopen.com
Genomic and Expression Alterations of  
Tumor Suppressor Genes in Meningioma Development, Progression and Recurrence 
 
249 
these tumors, aberrant promoter hypermethylation of CpG dinucleotides of several TSG has 
been described, including NF2 (26%), THBS1 (15-30%), TIMP-3 (24%), CDKN2A (10-17%), 
MGMT (6-16%), p73 (15%), ER (15%), GSTP1 (27%), RB1 (10%), DAPK1 (4%), VHL (4%) and 
CDKN2B (4-13%) (Bello, Amiñoso et al. 2004; Liu, Pang et al. 2005).  
2. Molecular alterations involved in the pathogenesis of meningiomas 
2.1 The NF2 gene 
The tumor suppressor gene NF2, located at 22q12.2, is considered the main candidate for the 
genesis of meningiomas (Martinez-Glez, Franco-Hernandez et al. 2009). Allelic losses of the 
22q12.2 chromosomal region encompassing the NF2 gene are found in 40–70% of the sporadic 
and the vast majority of NF2 associated meningiomas. Additionally, NF2 mutations are found in 
up to 60-70% of tumors, consistent with a classic two-hit mechanism of tumor suppressor gene 
inactivation (Ruttledge, Sarrazin et al. 1994). Most of these NF2 mutations are small insertions, 
deletions, or nonsense mutations affecting splicing sites, with a frequency of NF2 mutations 
roughly equal among different WHO grades, suggesting that it represents an important initiation 
rather than progression-associated alteration (Wellenreuther, Kraus et al. 1995).  
 
 
Fig. 1. Histopathological images of a WHO grade I secretory meningioma (A), a WHO grade 
I fibrous meningioma (B), a WHO grade II atypical meningioma (C), and a WHO grade III 
anaplastic meningioma (D). 
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In contrast, differences in the frequency of NF2 alterations have been noted based on variant 
histology, with higher rates in fibroblastic, transitional and psammomatous than in 
meningothelial or secretory grade I meningiomas (Wellenreuther, Kraus et al. 1995; 
Hansson, Buckley et al. 2007; Mawrin and Perry 2010). Thus, NF2 alterations appear to play 
a preferential role in the mesenchymal like phenotype of meningiomas. Support for this 
comes from the observation that non-NF2 meningioma families are more likely to develop 
meningothelial tumors. 
Transcriptional silencing by hypermethylation of CpG islands in the promoter region has 
been accepted as an alternative mechanism to genetic inactivation of tumor-suppressor 
genes. In fact, site directed mutagenesis demonstrated that a 70-bp region on the NF2 
promoter (-591 to -522 bp from the transcription start site) was essential for the basic 
expression of the NF2 gene (Kino, Takeshima et al. 2001). At least three CpG sites within this 
region (at positions -591, -586 and -581) appeared to be of particular importance for silencing 
of the NF2 gene upon methylation in schwannomas, with the methylation status consistent 
with the expression/silencing of NF2 mRNA. 
In this sense, aberrant methylation of the NF2 gene was detected as the sole alteration in 
samples of sporadic meningiomas, most of which from grade I tumors (Lomas, Bello et al. 
2005). Methylation analysis in two other studies, however, concluded that methylation of 
the NF2 promoter is unlikely to play a major role in the silencing of the NF2 gene in 
meningiomas (van Tilborg, Morolli et al. 2006; Hansson, Buckley et al. 2007). 
Alternatively, the NF2 gene may also be inactivated in meningiomas by increased calpain-
mediated proteolysis of merlin. Kimura et al. demonstrated cleavage of merlin by the 
ubiquitous protease calpain in meningioma tumors, together with considerable activation of 
the calpain system resulting in the loss of merlin expression (Kimura, Koga et al. 1998). 
The protein product of the NF2 gene is termed merlin or schwannomin, and meningiomas 
with associated NF2 alterations commonly result in a truncated, non-functional merlin 
protein. Merlin is a member of the 4.1 family of membrane-associated proteins, which also 
includes proteins ezrin, radixin and moesin. These proteins contribute to the interaction 
between glycoproteins of the cellular surface and the actin cytoeskeleton, functioning to link 
cell surface signaling to intracellular pathways (Curto and McClatchey 2008). Thus, 
alterations in merlin may subtantially affect cell shape and might favor the appearance of a 
more mesenchymal-like phenotype rather than the epithelioid one, seen more commonly in 
NF2 intact meningiomas.  
2.2 DAL1/4.1B, a member of the 4.1 protein family 
In addition to NF2, another gene coding for a member of the 4.1 family of proteins is DAL1. 
This gene encodes for the Protein 4.1B, located on chromosome 18p11.3. DAL1 gene is 
generally expressed at high levels in the brain and low levels in the kidney, intestine and 
testicles (Martinez-Glez, Franco-Hernandez et al. 2008).  
DAL1 loss, together with reduced protein expression of its gene product was detected in 
sporadic meningiomas, affecting more than 70% of tumors regardless of histological grade 
(Gutmann, Donahoe et al. 2000; Perry, Cai et al. 2000).  
This frequency is similar to that of NF2 absence of protein expression, suggesting that DAL1, 
similarly to NF2, could play an important role as an early event in the tumorigenesis of 
meningiomas.  
The similarity between the DAL1 protein and merlin, with their high levels of expression in 
the brain and their recurrent loss in meningiomas, led to a mutational study of DAL1 in a 
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series of sporadic meningiomas (Martinez-Glez, Bello et al. 2005). The low mutational 
frequency of this gene discounts sequence variations in DAL1 as the main mechanism 
underlying participation of this gene in the neoplastic transformation of meningiomas, and 
suggests that other inactivating mechanism, such as epigenetic changes, may participate in 
DAL1 silencing (Martinez-Glez, Bello et al. 2005).  
Additional analyses have shown that DAL1 suppresses the growth and cellular proliferation 
in meningiomas by activating, among others, the Rac1-dependent c-Jun-NH(2)-kinase 
signaling pathway (Martinez-Glez, Franco-Hernandez et al. 2008). However, the fact that 
transgenic mice lacking DAL1 do not develop tumors (Yi, McCarty et al. 2005), suggests that 
DAL1 alterations may represent an early progression associated rather than an initiation 
event for the development of meningiomas. This suggestion is also supported by the 
observation of losses of chromosome 18 not preferentially of the 18p11.3 region, but instead 
associated with clinically aggressive tumors. 
The absence of expression of two proteins of the Protein 4.1 family in most of sporadic 
meningiomas suggests that membrane-associated alterations are important events for the 
development and/or progression of meningiomas. Future experiments however would be 
necessary to address the functional role of these proteins in leptomeningeal and 
meningioma cells which may lead to define membrane- or cytoskeletal-associated pathways 
in tumorigenesis of meningiomas. 
2.3 TSCL1 and 14-3-3 are DAL1/4.1B interacting proteins 
A potential interaction with protein 4.1B has been reported for the Tumor Suppressor in Lung 
Cancer-1 (TSLC1) gene, prompting the study of TSCL1 in meningiomas. TSCL1 was 
originally identified as a transmembrane protein involved in specifying cell adhesion. 
TSLC1 interacts with the actin filament through DAL-1 at the cell-cell attached site where 
the complex formation of TSLC1 and DAL-1 is dependent on the integrity of actin 
cytoskeleton (Yageta, Kuramochi et al. 2002).  
Surace et al. demonstrated that TSCL1 is expressed in human leptomeningeal tissues, but is 
absent in 30% to 50% of benign meningiomas, 70% of atypical, and 85% of anaplastic 
meningiomas. Atypical meningiomas with high proliferative indices and most of WHO 
grade III meningiomas showed loss of TSCL1 expression, while atypical meningiomas with 
brain invasion but low mitotic index had a similar frequency of loss to that of the benign 
meningiomas (Surace, Lusis et al. 2004).  
Moreover, these authors reported a strong correlation between loss of TSCL1 expression and 
decreased patient survival. When WHO grade II were stratified by their TSCL1 expression 
status, TSCL1 loss was correlated with reduced patient survival, irrespective of mitotic 
index. These findings raise the possibility that TSCL1 may be an independent predictor of 
survival for patients with atypical meningioma (Surace, Lusis et al. 2004). 
Similarly, other study identified 14-3-3 as a 4.1B–specific interacting protein (Yu, Robb et al. 
2002). The 14-3-3 family of proteins are adaptor proteins involved in signal transduction 
regulation, with a role in cell growth, survival or apoptosis. However, impaired 14-3-3 
seems not to affect 4.1B function, suggesting additional proteins involved in 4.1B signaling. 
The potential importance of 14-3-3 proteins for meningioma growth control is underlined by 
a recent report showing reduced immunoexpression of certain 14-3-3 protein isoforms in 
aggressive meningiomas (Mawrin and Perry 2010). Thus, the precise roles of protein 14-3-3 
interactions with 4.1B have yet to be determined. 
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2.4 Other 22q tumor suppresor genes 
The close association of NF2 mutations in meningiomas with allelic loss on chromosome 22 
suggests that NF2 is the major meningioma tumor suppressor gene on that chromosome 
(Xiao, Gallagher et al. 2005; van Tilborg, Morolli et al. 2006; Simon, Boström et al. 2007; 
James, Lelke et al. 2008; Striedinger, VandenBerg et al. 2008; Martinez-Glez, Franco-
Hernandez et al. 2009; Shen, Nunes et al. 2009). Nonetheless, deletion studies of 
chromosome 22 have detected losses and translocations of genetic material outside the NF2 
region, thus raising the possibility of other meningioma genes residing on chromosome 22. 
Candidate genes, among others, include BAM22, BCR and TIMP3 (Fig 2). 
BAM22 gene belongs to the human β-adaptin gene family. Adaptins are essential for the 
formation of clathrin coated vesicles in the course of intracellular transport of receptor-
ligand complexes.  
The BAM22 gene has been proposed as a second chromosome 22 locus important in 
meningioma development, after the neurofibromatosis type 2 gene (Peyrard, Fransson et al. 
1994; Guilbaud, Peyrard et al. 1997). 
Recently, reduced expression of breakpoint cluster region (BCR) mRNA was found. It has 
appeared to be downregulated in meningiomas with loss of heterozygosity of 22q. The  
BCR gene is an extremely interesting tumor suppressor candidate, since NF2 and BCR 
proteins perform similar functions (Wozniak, Piaskowski et al. 2008). BCR contains a 
serine/threonine kinase that functions as a GTPase-activating protein for p21. The 
inactivation of BCR as well as NF2 might lead to hyperactivation of RAC pathway, and 
together with the downregulation of the gene, suggest that BCR can be considered as a 
tumor suppressor candidate (Wozniak, Piaskowski et al. 2008). 
Matrix metalloproteinases (MMPs) are proteases capable of degrading extracellular matrix 
proteins. They are involved in the cleavage of cell surface receptors, the release of apoptotic 
ligands, and chemokine/cytokine inactivation, playing an important role on cell 
proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis and 
host defense. The TIMP3 (tissue inhibitor of metalloproteinase 3) gene on 22q12.3 codes for a 
protein that can specifically inhibit MMPs by covalent binding to the active site of the 
enzymes and thus reduces the invasion and the metastatic potential of tumor cells. In 
addition, overexpression of TIMP3 in vitro induces apoptosis and suppresses tumor growth 
and angiogenesis in different cell line models (Barski, Wolter et al. 2010). 
Numerous reports have demonstrated the loss of expression of TIMP3 in meningiomas 
using diverse approaches, such as microarray expression profiling, real-time reverse 
transcription PCR analyses or immunohistochemical protein expression studies (Carvalho, 
Smirnov et al. 2007; Fèvre-Montange, Champier et al. 2009; Barski, Wolter et al. 2010; Pérez-
Magán, Rodríguez de Lope et al. 2010). In addition, hypermethylation of the promoter 
region of TIMP3 gene has been analyzed showing controversial results (Bello, Amiñoso et al. 
2004; Liu, Pang et al. 2005). Recently, TIMP3 hypermethylation has been associated with 
meningioma progression, due to 67% of anaplastic meningiomas showed hypermethylation 
of the TIMP3 promoter, while this was true for only 22% of atypical and 17% of benign 
meningiomas. In addition, TIMP3 hypermethylation and transcriptional downregulation 
were found exclusively in meningioma with allelic losses on 22q12, in contrast to NF2 
mutation (Barski, Wolter et al. 2010; Pérez-Magán, Rodríguez de Lope et al. 2010). Taken 
togheter, all these results point out TIMP3 as an important candidate tumor suppressor gene 
located in 22q, besides NF2. 
Other genes located on chromosome 22q have also been proposed as possible TSG 
candidates: MN1, SMARCB1, LARGE, RRP22 and GAR22. The MN1 gene (22q12.1) was 
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found to be disrupted by a balanced translocation in meningioma, although more recent 
studies suggest a role as a co-activator of the oncogenic transcription than as a TSG 
(Martínez-Glez V. 2007; Perry, Louis et al. 2007). The protein encoded by the SMARCB1 gene 
(22q12.3) is part of a complex that relieves repressive chromatin structures, allowing the 
transcriptional machinery to access its targets more effectively.  
 
 
Fig. 2. View of chromosome 22 including candidate TSG involved in meningiomas. 
This gene has been found to be a tumor suppressor, and mutations in it have been 
associated with malignant rhabdoid tumors (Oruetxebarria, Venturini et al. 2004; Martinez-
Glez, Franco-Hernandez et al. 2008). In addition, the LARGE gene (22q12.3) might be 
involved in genomic rearrangements associated with tumors (Martinez-Glez, Franco-
Hernandez et al. 2008). This gene, which is one of the largest in the human genome, encodes 
a member of the N-acetylglucosaminyltransferase gene family. Other genes identified in the 
long arm of chromosome 22 are tumor suppressor genes and are located on 22q12.2, near to 
NF2: RRP22 and GAR22. The RRP22 have been identified as a novel, farnesylated member of 
the Ras superfamily that exhibits the properties of a potential neural-specific tumor 
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suppressor and is implicated in the regulation of nucleolar transport processes (Elam, 
Hesson et al. 2005). The protein encoded by the gene GAR22, a member of the GAS2 family, 
is an actin-associated protein expressed at high levels in growth-arrested cells (Goriounov, 
Leung et al. 2003) 
3. Molecular alterations involved in meningioma progression 
Meningiomas are generally thought to progress from low-grade to high-grade tumors, 
although this is not always easy to demonstrate clinically. Indeed, none of the typical 
genetic aberrations found in meningiomas have acquired clinical relevance. Nevertheless, 
the analysis of the genetic aberrations in relation to the histologic grade pointed out that 
malignant progression in meningiomas is associated with the acquisition of additional 
genetic changes, in a stepwise model for acquisition of chromosomal gains and losses 
during meningioma progression (Weber, Boström et al. 1997).  
As mentioned before, chromosome 22 monosomy or 22q deletions are the most frequent 
genetic alteration found in meningiomas, and thus are considered as an early event involved 
in the pathogenesis of meningiomas. Secondary to 22q alterations, genetic changes most 
frequently associated with meningiomas include 1p and 14q deletions. Moreover, these 
alterations have been related to tumoral progression in meningiomas (Leone, Bello et al. 
1999; Buckley, Jarbo et al. 2005; Espinosa, Tabernero et al. 2006; Maillo, Orfao et al. 2007; 
Martinez-Glez, Franco-Hernandez et al. 2008).  
Genetic alterations in atypical meningiomas include allelic losses of 1p, 6q, 10, 14q and 18q and 
gains of 1q, 9q, 12q, 15q, 17q and 20q. Anaplastic meningiomas frequently show losses of 6q, 
10q and 14q as well as gains and/or amplifications on 17q23 (Weber, Boström et al. 1997; Louis 
DN and JJ 2000; Martínez-Glez V. 2007; Martinez-Glez, Franco-Hernandez et al. 2008). 
Genetic alterations in atypical meningiomas include allelic losses of 1p, 6q, 10, 14q and 18q and 
gains of 1q, 9q, 12q, 15q, 17q and 20q. Anaplastic meningiomas frequently show losses of 6q, 
10q and 14q as well as gains and/or amplifications on 17q23 (Weber, Boström et al. 1997; Louis 
DN and JJ 2000; Martínez-Glez V. 2007; Martinez-Glez, Franco-Hernandez et al. 2008). 
4. Altered regions in meningioma progression 
4.1 Loss of 1p  
Loss of 1p represent the most frequent genetic alteration secondary to chromosome 22 
tumor suppressor gene inactivation (NF2/others), which seems to participate in the genesis 
of the aggressive meningiomas, as this anomaly is found predominantly in atypical (40-76%) 
and anaplastic forms (70-100%), as opposed to benign meningiomas (13-26%) (Bello, de 
Campos et al. 1994; Bello, de Campos et al. 2000; Maillo, Orfao et al. 2007; Pérez-Magán, 
Rodríguez de Lope et al. 2010).  
Loss of heterozygosity assays revealed two regions mainly involved in meningioma 
progression, including 1p36 and 1p32-34, although other regions less frequently lost were 
also detected at 1p22 and 1p21.1-p13 (Bello, de Campos et al. 2000). Furthermore, a 
comprehensive study of DNA copy number profiling analysis in meningiomas revealed 
three 1p and one 1q candidate sites of genomic imbalance on chromosome 1, which may be 
relevant for meningioma development and progression (Buckley, Jarbo et al. 2005). 
Therefore, these regions may contain one or more tumor suppressor genes important for 
meningioma progression. Candidate genes have been pointed out, among others: ALPL, 
TAp73, EPB41, RAD54L, GADD45A, CDKN2C, and LMO4. 
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Fig. 3. Molecular alterations associated with tumor progression in meningiomas. 
4.1.1 Candidate genes located at 1p36: ALPL and TAp73 
The ALPL gene maps to chromosome 1p36.12, and codes for the tissue non-specific form of 
alkaline phosphatases (APL). In contrast to the brain tissue, the meninges constitutionally 
exhibit a strong cellular activity of this enzyme, being present in both cytoplasmic 
membrane and cytosol. Alterations of 1p together with loss of enzyme activity were found 
in meningiomas, revealing this gene as a good candidate TSG (Müller, Henn et al. 1999). 
Additionally, the functional expression of the alkaline phosphatase has been related to the 
mineralization capacity observed in meningiomas, and its loss of expression was associated 
with increased tumor aggressiveness (Müller, Henn et al. 1999; Sayagués, Tabernero et al. 
2007). Further studies of this gene, however, are required. 
TAp73 encodes for a protein with significant homology to the p53 tumor suppressor gene 
throughout its DNA-binding, transactivation, and oligomerization domains. Despite this 
similarity, animal models showed that p73 is an important player in neurogenesis, sensory 
pathways and homeostatic control, but its function in tumorigenesis is controversial (Moll 
and Slade 2004). Mutational analyses of p73 have been performed in a wide variety of tumor 
types and, up to date, p73 is not the target of inactivating mutations in human cancers, 
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including meningiomas (Lomas, Bello et al. 2001). Aberrant p73 hypermethylation was also 
analyzed in meningiomas, showing that although it was more frequent in those tumors with 
1p deletion, an independent association of p73 promoter methylation with the grade of 
malignancy could not be established (Lomas, Amiñoso et al. 2004). Nevertheless, another 
study detected 1p LOH and p73 promoter hypermethylation in the malignantly transformed 
tumors but not in the lower-grade primary ones (Nakane, Natsume et al. 2007). 
4.1.2 Candidate genes located at 1p33-32: EPB41, RAD54L and CDKN2C 
The 4.1R gene (1p33-32), or EPB41, belongs to the Protein 4.1 family, which also includes the 
products of the NF2 and DAL1 genes, merlin and Protein 4.1B, respectively. EPB41 was 
described to function as a tumor suppressor gene in meningiomas, through the 
demonstration of both, allelic loss of the 4.1R gene by FISH, and loss of Protein 4.1R 
expression in sporadic meningiomas and cell lines by using immunohistochemical assays 
and western blotting. Moreover, in vitro functional experiments in meningioma cell lines 
supported a tumor suppressor function in these tumors (Robb, Li et al. 2003). Opposite 
results were obtained by Piaskowski et al. (2005) who find no change of mRNA expression 
between meningionmas with 1p LOH and those without it (Piaskowski, Rieske et al. 2005).  
The human homologue of the Saccharomyces cerevisiae RAD54 DNA repair gene (hRAD54) is 
located at 1p32 (Rasio, Murakumo et al. 1997). The protein encoded by this gene plays a role 
in homologous recombination related repair of DNA double-strand breaks. The RAD54L 
gene was proposed as a candidate for a tumor-associated gene in neoplasms that display 1p 
allelic imbalance, such as in meningiomas. However, mutational analysis of this gene in a 
series of 25 oligodendrogliomas and 18 meningiomas failed to identify any deletions or 
inactivating mutations of the gene (Mendiola, Bello et al. 1999; Bello, de Campos et al. 2000; 
Bello, de Campos et al. 2000). 
The p18INKC gene (CDKN2C, 1p32) is a member of the INK4 family of cycline-dependent 
kinase (CDK) inhibitors, together with p16INK4a, p15INK4b, and p19INK4d. These inhibitors 
participate in cell cycle regulation by inhibiting the activity of CDK–cyclin complexes. 
CDKN2C was considered a potential tumor suppressor gene in meningiomas due to its 
similarities with other members of the INK4 family.  
However, absence of genetic and epigenetic alterations of CDKN2C, together with no altered 
protein expression in meningiomas ruled out this gene as the major target of the frequent 1p32 
losses in meningiomas (Santarius, Kirsch et al. 2000; Boström, Meyer-Puttlitz et al. 2001).  
4.2 Loss of 14q 
Another frequent cytogenetic anomaly in meningiomas is the loss of 14q, which shows 
increasing frequencies paralleling the increase in tumor grade. Therefore, about a third of 
benign meningiomas show the 14q loss, while 40-57% and 55-100% of atypical and 
anaplastic tumors, respectively, present this loss (Weber, Boström et al. 1997; Ozaki, 
Nishizaki et al. 1999; Cai, Banerjee et al. 2001; Simon, Boström et al. 2007; Tabernero, Maillo 
et al. 2008). Various studies have described different regions ranging from 14q21 to 14q32 
(Weber, Boström et al. 1997; Martinez-Glez, Franco-Hernandez et al. 2008). To date, 
however, the actual targets of this chromosomal lost have been remained large elusive and 
thus, no 14q tumor suppressor genes have been confirmed in meningiomas. Nevertheless, 
several 14q tumor suppressor candidate genes have been evaluated, namely NDRG2 and 
MEG3. 
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4.2.1 NDRG2 (14q11.2) 
This gene is a member of the N-myc downstream-regulated gene family. The protein 
encoded by this gene is a cytoplasmic protein that has been found involved in a variety of 
cancers. It is expressed in low-grade gliomas, but present at low levels or absent in primary 
glioblastoma. In meningioma tumors, Lusis et al. used a differential gene expression 
approach leading to the identification of NDRG2 as a potential meningioma associated 
tumor suppressor gene that is inactivated during meningioma progression. Furthermore, 
these authors showed that the loss of NDRG2 expression was significantly associated with 
hypermethylation of the NDRG2 promoter (Liu, Pang et al. 2005; Lusis, Watson et al. 2005). 
4.2.2 MEG3 (14q32) 
Recently, it has been reported that the maternally expressed gene 3 (MEG3), which encodes 
a noncoding RNA, could be a tumor suppressor gene at chromosome 14q32 involved in 
meningioma progression (Zhang, Gejman et al. 2010). Zhang et al. showed that MEG3 is 
expressed in normal human meningothelial cells, but is low or absent in the majority of 
meningioma tumors and meningioma cell lines. Moreover, loss of MEG3 RNA expression as 
well as loss of MEG3 gene copy number is more common in higher grade meningiomas, and 
there is an overall increase in CpG methylation in tumors associated with tumor grade. 
Finally, MEG3 RNA expression in human meningioma cell lines strongly suppresses tumor 
cell growth in vitro, which is independent of merlin, and activates p53-mediated 
transactivation. As an imprinted gene encoding a noncoding RNA, MEG3 seems to suppress 
tumor development in meningioma via entirely novel mechanisms (Zhang, Gejman et al. 
2010). 
4.3 Alterations of 9p: CDKN2A, p14
ARF
, and CDKN2B genes 
Losses of chromosome 9p, particularly at the 9p21 region, were frequently found in 
anaplastic meningiomas but only rarely in atypical and benign meningiomas (Weber, 
Boström et al. 1997; Boström, Meyer-Puttlitz et al. 2001). Alterations of 9p21 have been 
found to represent losses of the well-known tumor suppressor genes CDKN2A (p16INK4a), 
p14ARF, and CDKN2B (p15INK4b), involved in control of cell-cycle, and inactivated at high 
frequency in a large variety of human tumors.  
Analysis of the alterations (deletions, mutations and promoter hypermethylation) of these 
tumor suppressor genes in meningiomas revealed that most of anaplastic meningiomas either 
show homozygous deletions, mutations (mainly in CDKN2A and p14ARF), or lack of expression 
of one or more of these genes. Therefore, inactivation of the G1/S-phase cell-cycle checkpoint 
is an important feature of meningiomas of advanced stage (anaplastic) that likely contributes 
to the rapid growth and malignant behavior of these tumors, and point it out as a progression 
associated alteration in meningiomas (Boström, Meyer-Puttlitz et al. 2001). Moreover, by using 
FISH, other authors reported higher frequencies of 9p or CDKN2A alterations in meningiomas, 
mostly in anaplastic tumors (74% of anaplastic meningiomas, 52% of atypical, and 17% of 
benign meningiomas). Interestingly, in this study CDKN2A deletion was strongly associated 
with outcome, with 9p deleted anaplastic tumors showing a high risk ratio for death. On the 
other hand, absence of deletion identified a subset of anaplastic meningioma patients (26%) 
with prolonged survival (Perry, Banerjee et al. 2002). Therefore, these studies support that 
chromosome 9p21 deletions are associated with malignant progression of meningiomas, and 
that it is a poor prognostic factor in anaplastic meningiomas. 
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4.4 Amplification of 17q region 
Amplification of the 17q21-qter region was associated with the mechanism of progression 
from atypical to anaplastic tumors, due to high-level amplification on 17q was identified in 
48-60% of anaplastic meningiomas and in few or none of atypical and benign tumors 
(Weber, Boström et al. 1997).  
The S6 kinase (S6K) gene (17q23) was evaluated as the target of the 17q amplification in 
anaplastic meningiomas, based on its location (Cai, James et al. 2001) and on the 
observation of increased S6K mRNA expression in these tumors compared with benign 
meningiomas (Surace, Lusis et al. 2004). Experiments performed in meningioma cell lines 
revealed no effect of S6K overexpression on meningioma cell growth, motility, or 
adhesion in vitro, although S6K overexpression resulted in increased tumor size in vivo 
(Surace, Lusis et al. 2004). Therefore, although previous studies revealed no high-level 
amplification of the S6K candidate gene (Büschges, Ichimura et al. 2002), the study of 
Surace and coworkers suggests that S6K may be functionally important for meningioma 
progression (Surace, Lusis et al. 2004). Further studies are needed to map the 17q23 
amplicon to determine whether additional genes in this region are amplified in high-
grade meningiomas. 
5. Molecular pathology of meningioma recurrence 
As mentioned before, histological grade and extent of surgical resection are the two most 
important variables in meningiomas. However, 5% and 40% of benign and atypical tumors, 
respectively, recur within 5 years even after total gross resection (Riemenschneider, Perry et 
al. 2006). 
The loss of 1p and 14q was suggested as one of the alterations observed in meningioma 
recurrence (Maillo, Orfao et al. 2007; Tabernero, Espinosa et al. 2007; Pfisterer, Coons et al. 
2008). Recently, a higher recurrence rate of meningiomas with 1p36 loss (33%) than that of 
meningiomas with normal chromosome 1p36 (18%) has been reported (Ruiz, Martínez et al. 
2010). In addition, a differential gene expression pattern that distinguishes between original 
and recurrent meningiomas identified a subset of meningioma recurrence associated genes, 
and reported novel candidate genes of recurrence. Most of these candidate genes are located 
at chromosomal regions previously associated with a higher risk of recurrence or malignant 
progression of meningiomas: 1p, 6q and 14q (Fig 4) (Pérez-Magán, Rodríguez de Lope et al. 
2010). Furthermore, an additional comprehensive copy number and gene expression study 
also identified 6q and 14q loss significantly more common in recurrent tumors and 
associated with anaplastic histology (Lee, Liu et al. 2010). Finally, an abnormal cDNA gene 
expression pattern was identified associated with meningiomas displaying genomic 
deletions at 1p and 14q (Martínez-Glez, Alvarez et al. 2010). 
In general, these recurrence-associated genes are underexpressed relative to non-tumoral 
meningothelial tissue, denoting an overall underexpression of genes in recurrent 
meningiomas (Lee, Liu et al. 2010; Pérez-Magán, Rodríguez de Lope et al. 2010). Conversely, 
overexpression of few genes were identified in recurrent meningiomas, remarkably genes of 
the histone cluster 1 (6p) (Pérez-Magán, Rodríguez de Lope et al. 2010). 
Among the 1p candidate genes, the LMO4 (LIM-only protein 4) gene is one of the candidates 
consistently reported on several gene expression studies on meningioma recurrence 
(Carvalho, Smirnov et al. 2007; Fèvre-Montange, Champier et al. 2009; Pérez-Magán, 
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Rodríguez de Lope et al. 2010) and progression (Carvalho, Smirnov et al. 2007; Fèvre-
Montange, Champier et al. 2009). This gene maps to 1p22.3 and belongs to a family of four 
mammalian LMO proteins which are short transcriptional regulators that play roles in 
mammalian development; LMO4 is required for the proper closure of the neural tube 
(Lee, Jurata et al. 2005). Two members of the family, LMO1 and LMO2 act as oncogenes in 
acute lymphoblastic leukemia and previous studies have defined LMO3 as an oncogene in 
neuroblastoma (Lu, Lam et al. 2006). Furthermore, overexpression of LMO4 has been 
reported to induce cell invasion and to be associated with outcome in breast cancer, 
especially in estrogen receptor negative tumors (Sum, Segara et al. 2005). In pancreatic 
tumors it was also found overexpressed (Sum, Segara et al. 2005; Yu, Ohuchida et al. 
2008), but high LMO4 expression was associated with survival advantage (Murphy, 
Scarlett et al. 2008). 
 
 
Fig. 4. Location of the genes differentially expressed in original and recurrent meningiomas 
on chromosomes 1, 6 and 14, plotted according to their map position. Genes with lower 
(green) and higher (red) levels of expression in recurrences than in original tumors are 
shown on the left and right, respectively, of the chromosome ideogram.  
Surprisingly, underexpression of LMO4 was detected associated with progression and 
recurrence of meningiomas, as reported on gene expression profiling studies (Carvalho, 
Smirnov et al. 2007; Fèvre-Montange, Champier et al. 2009); (Pérez-Magán, Rodríguez de 
Lope et al. 2010). A recent report suggested that LMO4 modulates TGF- signaling through 
its interaction with receptor-activated SMADs (Lu, Lam et al. 2006), however its role in 
meningiomas should be further studied.  
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Fig. 5. Immunohistochemistry of meningioma samples with (A) positive and (B) negative 
expression of LMO4 (original magnification, ×400). 
6. Signal transduction pathways altered in meningiomas 
The hallmarks of cancer proposed by Hanahan and Weimberg in a multistep process in 
which cancer cells acquire the subsequent features that enable them to become tumorigenic 
and ultimately malignant include: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
and activating invasion and metastasis (Hanahan and Weinberg 2011). Abnormalities of 
these processes involve alteratinos of multiple cell signaling pathways affected in 
meningioma tumorigenesis, such as the beta-catenin/WNT, NOTCH, TGF-beta or p53 
pathways (Ragel and Jensen 2010). 
6.1 The beta-catenin/WNT pathway 
The Wnt (wingless) signaling pathway involves proteins that regulate the production of 
Wnt signaling molecules, their interaction with receptors, and the physiological responses 
that result from the exposure of cells to the extracellular Wnt ligands. The series of events 
that occur when Wnt proteins bind to cell-surface receptors of the Frizzled family ultimately 
results in a change of the amount of β-catenin that reaches the nucleus. 
Studies using microarray-based gene expression profiling identified altered expression of 
genes associated with the beta-catenin/WNT signaling pathway in meningiomas with losses 
of 14q, such as the genes for beta-catenin (CTNNB1), the regulatory subunit of cyclin-
dependent kinase 5 (CDK5R1), ectodermal-neural cortex 1 (ECN1) and cyclin D1 (CCND1), 
which were upregulated in atypical and anaplastic meningiomas (Wrobel, Roerig et al. 
2005). Increased CTNNB1 and CDK5R1 mRNA levels may result in aberrant WNT pathway 
activity due to increased levels of cytoplasmic β-catenin, which may translocate to the 
nucleus, where it functions as a transcriptional activator of a number of genes. 
The beta-catenin/WNT pathway has also been recently implicated as important in 
meningioma recurrence, showing loss of expression of SFRP1 (Wrobel, Roerig et al. 2005; 
Pérez-Magán, Rodríguez de Lope et al. 2010). This gene belongs to the family of the secreted 
frizzled-related proteins (SFRP), which are able to downregulate Wnt signaling by forming 
an inhibitory complex with the Frizzled receptors. The role of SFRP1 as a tumor suppressor 
has been proposed in many other cancers (Caldwell, Jones et al. 2004; Chung, Lai et al. 
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2009). In gliomas, lower expression of SFPR1 and promoter hypermethylation has recently 
been reported (Götze, Wolter et al. 2009). 
6.2 The Notch signaling pathway 
The Notch signaling pathway consists of a family of four cell-spanning proteins that enable 
extracellular-to-intracellular signaling. Ligand proteins bind to the extracellular portion of 
the Notch protein, resulting in the proteolytic cleavage and release of the intracellular 
portion. This cleaved portion translocates to the cell nucleus to alter gene expression. This 
signaling pathway is important for cell–cell communication and has multiple functions 
during development as well as adult cellular functions. This signaling pathway is 
dysregulated in many cancers.  
Cuevas et al. have identified three components of the Notch signaling pathway: the 
transcription factor, hairy and enhancer of Split1 (HES1), which is induced in meningiomas 
of all grades; and two members of the Groucho/transducin-like enhancer of Split family of 
corepressors, TLE2 and TLE3, altered in high grade meningiomas (Cuevas, Slocum et al. 
2005). 
Furthermore, it has been reported that activated Notch1 and Notch2 receptors induced 
endogenous HES1 expression and were associated with tetraploidy in meningiomas. 
Therefore, a novel function for the Notch signaling pathway in generating tetraploidy and 
contributing to chromosomal instability in meningiomas was reported. This abnormal 
Notch signaling pathway may be an initiating genetic mechanism for meningioma 
tumorigenesis and potentially may promote tumor development (Baia, Stifani et al. 2008). 
6.3 p53 signaling pathway 
Cell-cycle proteins in human tumors comprise both positive and negative regulators. 
Negative cell cycle regulators include tumor-suppressor genes, of which p53 has been 
widely studied in different kinds of human tumors. The p53 gene is located on chromosome 
17p13.1 and composed of 11 exons.  
p53 protein is a key player in the cellular response to stress. It is a nuclear phosphoprotein 
that by binding to DNA in a sequence-specific manner functions as a transcription factor 
regulating a wide diversity of cellular processes such as cell proliferation, differentiation, 
apoptosis, senescence, DNA repair, or changes in metabolism.  
p53 responds to various forms of cellular stresses by activating the expression of 
downstream genes that inhibit growth, invasion and/or apoptosis, thus functioning as a 
tumor suppressor (Vousden and Prives 2009). 
The expression of p53 protein is mainly regulated at the post-transcription stage and 
maintained at a very low level in normal cells. MDM2 is an important regulator of p53; it binds 
to p53 and inhibits its function by concealing the p53 activation domain and by promoting its 
degradation. In response to DNA damage, the MDM2 binding site of p53 is phosphorylated 
and the p53–MDM2 interaction is attenuated inducing the rapid accumulation of p53, relieved 
from MDM2-mediated suppression. The p14ARF protein, another component of the p53 
pathway, binds to the p53/MDM2 complex and inhibits MDM2-mediated degradation of p53, 
which indicates that p14ARF is an upstream regulator of p53 via MDM2. In addition, p53 
downregulates the expression of p14ARF and MDM2, in an autoregulatory feedback loop 
between p53, MDM2, and p14ARF (Zhang, Xiong et al. 1998).  
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Analysis of this pathway in meningiomas has shown that deregulations of p14-MDM2-p53 
pathway may contribute to the malignant progression of meningioma. Amatya et al. found 
that methylation of p14ARF gene is more common to atypical and anaplastic meningioma 
than in benign meningiomas (Amatya, Takeshima et al. 2004). In addition, high expression 
of p53 was found in atypical and anaplastic meningiomas (Amatya, Takeshima et al. 2001), 
although low frequency or absence of mutation of p53 gene was reported by these and other 
authors (Weber, Boström et al. 1997). Moreover, frequencies of p14ARF hypermethylation of 
the promoter region increases with the tumoral grade in meningiomas, with higher 
expression of MDM2 protein the cases with methylation of p14ARF gene (Amatya, Takeshima 
et al. 2004). 
6.4 TGF- signaling pathway 
The TGF beta signaling pathway is involved in a wide range of cellular process such as cell 
growth, differentiation and apoptosis among other cellular functions. Therefore, it is a very 
heavily regulated pathway. The ligands of the TGF-beta superfamily bind to a type II 
receptor, recruiting and phosphorylating a type I receptor. As a consequence, the type I 
receptor activates receptor-regulated SMADs (e.g. SMAD2, SMAD3) which can now bind 
coSMADs (SMAD4). These complexes accumulate in the nucleus where they act as 
transcription factors and participate in the regulation of target gene expression. 
In vitro studies of this pathway in meningioma cell lines suggest that TGF- has an 
inhibitory effect on meningioma proliferation, possibly through Smad 2/3 apoptotic 
pathways (Johnson, Okediji et al. 2004). However, a recent study of the most relevant 
molecules of the TGF-beta pathway on meningioma tumors concluded that only attenuated 
TGF-βRIII expression and TGFB growth inhibition may occur in select higher grade 
meningiomas (Johnson, Shaw et al. 2011). 
7. Conclusions 
Meningiomas show a broad range of histopathological patterns that in most of the tumors 
are featured by similar biological and clinical behaviors. Nevertheless, some difficulties 
still remain, particularly for designation of atypical WHO grade II meningiomas. In 
addition, different clinical outcomes and recurrence rates even within the same 
histopathological grade have been observed. Therefore, it is of relevance the identification 
of prognostic biomarkers for a proper individualized management of the patients. In these 
sense, useful genetic models for the mechanisms of tumorigenesis and progression in 
meningiomas have been described, proposing a number of candidate target genes. 
However, a big amount of genetic and epigenetic research still has to be done in order to 
identify patients at risk and to translate this information into effective forms of targeted 
therapies. 
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